Staar, Ophtec Address Panel’s Phakic IOL Endothelial Cell Loss Concerns
This article was originally published in The Gray Sheet
Executive Summary
FDA Ophthalmic Devices Panel concerns regarding endothelial cell loss associated with phakic intraocular lens implantation will delay review of Ophtec's Artisan phakic IOL by two months, the firm says
You may also be interested in...
Refractec Preparing For February Panel Review Of RF Presbyopia Treatment
Refractec expects FDA approval of its CK Blended Vision radio frequency procedure for presbyopia to increase its market opportunity by 18 mil. people
Refractec Preparing For February Panel Review Of RF Presbyopia Treatment
Refractec expects FDA approval of its CK Blended Vision radio frequency procedure for presbyopia to increase its market opportunity by 18 mil. people
Staar Warning Letter Presents Challenges For ICL Approval Timeline
Staar Surgical continues to anticipate approval for the Collamer ICL implantable contact lens by April, despite compliance issues raised in a Dec. 22 FDA warning letter